TICKERNERD
Menu
BLLNBLLNHealthcare · Diagnostics & Research

BLLN Stock Forecast: BillionToOne, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$95
−0.25% on the day

The 8 Wall Street analysts covering BillionToOne, Inc. hold a median 12-month price target of $125 — +31.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.5B
Ticker Nerd rank
15 / 100
Median analyst target
$125
Analysts covering
8
Total return, dividends reinvested
1W
+1.8%
1M
−28.3%
YTD
+16.1%
From high
−36.6%
From low
+48.4%
$64
$150
Range since 6 Nov 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

BLLN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BillionToOne, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
61
Value
59
Revisions
53
Growth
39
Accruals
27
Size
25
Issuance
12
Momentum
9
Volatility
4

Quality (61): The business earns solid, repeatable profits on what it owns.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BLLN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BLLN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 6 Nov 2025Adjusted close, US dollars
$60$80$100$120$140$160Jan 26Apr 26Jul 26BLLNHigh $145Median $125Low $90

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
6 Buy2 Hold0 Sell
Low $90Median $125High $145

The green dot is the last close — the median target sits +31.5% from it.

Recent analyst actionsNewest first

Of the 19 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
6 Aug 2026BTIGMaintainsBuy$142 → $130
6 Aug 2026JP MorganMaintainsOverweight$145 → $130
29 June 2026GuggenheimInitiatesBuy$120 → $125
29 June 2026GuggenheimInitiatesBuy—
13 May 2026GuggenheimMaintainsBuy—
7 May 2026BTIGMaintainsBuy—
7 May 2026JP MorganMaintainsOverweight—
30 Mar 2026GuggenheimMaintainsBuy—
5 Mar 2026BTIGMaintainsBuy—
5 Mar 2026GuggenheimReiteratesBuy—
5 Mar 2026Wells FargoMaintainsEqual-Weight—
10 Dec 2025BTIGReiteratesBuy—
10 Dec 2025JP MorganMaintainsOverweight—
1 Dec 2025BTIGInitiatesBuy—
1 Dec 2025JefferiesInitiatesHold—
1 Dec 2025JP MorganInitiatesOverweight—
1 Dec 2025Piper SandlerInitiatesOverweight—
1 Dec 2025StifelInitiatesBuy—
1 Dec 2025Wells FargoInitiatesEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BLLN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BLLN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+59.8%
Analysts raising
1
Analysts cutting
0
Fundamentals

BillionToOne, Inc. (BLLN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
133.8×

Cheaper than 5% of US stocks

Price / sales
11.3×

Cheaper than 13% of US stocks

Price / book
8.3×

Cheaper than 13% of US stocks

EV / EBITDA
81.2×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
64.4%

Higher than 90% of US stocks

Earnings growth (YoY)
64.4%

Higher than 79% of US stocks

Gross margin
70.5%

Higher than 83% of US stocks

Operating margin
5.0%

Higher than 55% of US stocks

Net margin
8.3%

Higher than 66% of US stocks

Returns & dividend
Return on equity
10.7%

Higher than 65% of US stocks

Return on assets
5.2%

Higher than 77% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BLLN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
BLLNBillionToOne, Inc.$4.5B
15
ADPTAdaptive Biotechnologies Corp.$4.2B
78
SHCSotera Health Co.$5.6B
96
GRALGRAIL, Inc.$3.6B
36
VCYTVeracyte, Inc.$3.4B
97
RDNTRadNet, Inc.$6.0B
35
WGSGeneDx Holdings Corp.$2.5B
47

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BillionToOne, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BLLN news & analysis

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

PRNewsWire · 18 Aug 2026positive

BillionToOne announced publication of a prospective, multi-site study in The Green Journal involving more than 2,200 pregnant carriers, demonstrating strong clinical performance of its cell-free DNA fetal risk assessment for recessive conditions in the general-risk population, with outcomes available for over 98% of eligible cfDNA results.

Why it matters — The study provides published clinical evidence supporting BillionToOne's cfDNA test as a primary screen for recessive conditions in general-risk pregnancies, which could strengthen the company's product positioning.

BillionToOne: A Softer Quarter After Heightened Expectations

Seeking Alpha · 7 Aug 2026negative

BillionToOne reported second-quarter results with strong year-over-year revenue growth but slower sequential growth, softer average selling prices, and significant margin compression versus Q1. The stock fell sharply after earnings despite the company maintaining full-year guidance.

Why it matters — BLLN watchers would care because near-term valuation appears less attractive after the sell-off, even though the company's growth story remains intact.

Why BillionToOne Plummeted 36%, Leading A Medtech Sell-Off

Investors Business Daily · 6 Aug 2026negative

BillionToOne's shares fell 36% on Thursday, leading a medical research stock sell-off, after the company reported its second-quarter results, which featured an earnings beat but no raise to its guidance.

Why it matters — A BillionToOne watcher would care because the sharp 36% drop and the absence of a guidance raise signal that investors were disappointed despite the quarterly earnings beat.

BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 6 Aug 2026neutral

BillionToOne (BLLN) reported its Q2 2026 earnings, with headline revenue and profit figures alongside analysis of key metrics compared to Wall Street estimates and year-ago values. The report highlights how the company's performance for the quarter ended June 2026 stacks up against analyst expectations and prior-year results.

Why it matters — BLLN watchers would care because the report shows whether the company's key operating metrics matched Wall Street's expectations and how they compare to the prior-year quarter.

Billiontoone Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

BillionToOne (NASDAQ: BLLN) reported 64% year-over-year revenue growth for the second quarter of 2026, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses. The molecular diagnostics company also reported positive operating income and free cash flow while reiterating its full-year revenue outlook.

Why it matters — A BLLN watcher would care because the company's accelerating revenue with positive operating income and free cash flow, along with a reaffirmed full-year outlook, signals improving financial health across its core business lines.

FAQ

Frequently asked questions about BLLN stock

What is the BLLN stock price forecast for 2026-2027?

The 8 Wall Street analysts covering BillionToOne, Inc. have a median 12-month price target of $125, with estimates ranging from $90 to $145. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BLLN stock a buy right now?

Of the 8 analysts covering BillionToOne, Inc., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BillionToOne, Inc. 15 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BLLN?

As at 22 Aug 2026, BillionToOne, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (61 of 100).

Will BLLN stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +31.5% from the last close, and Ticker Nerd's factor model ranks BillionToOne, Inc. 15 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BLLN stock forecast for 2030?

No analyst covering BillionToOne, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BLLN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $90 to $145 over the next 12 months.

What does BillionToOne, Inc. do?

BillionToOne, Inc. is a precision diagnostics company specializing in the development of advanced molecular diagnostic tests for healthcare applications.

What is the latest news on BLLN?

The most recent item we track (PRNewsWire, 18 Aug 2026): "Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions". BillionToOne announced publication of a prospective, multi-site study in The Green Journal involving more than 2,200 pregnant carriers, demonstrating strong clinical performance of its cell-free DNA fetal risk assessment for recessive conditions in the general-risk population, with outcomes available for over 98% of eligible cfDNA results.

Company

About BillionToOne, Inc.

BillionToOne, Inc. is a precision diagnostics company specializing in the development of advanced molecular diagnostic tests for healthcare applications. The company’s core innovation is its proprietary single-molecule next-generation sequencing (smNGS) platform, which enables highly sensitive and accurate detection and quantification of DNA molecules at the single-molecule level. This technological breakthrough underpins BillionToOne’s flagship product lines, including UNITY Complete, a non-invasive prenatal screening test that assesses fetal risk for chromosomal aneuploidies, recessive conditions such as sickle cell disease and cystic fibrosis, and fetal antigens, all from a single maternal blood draw. Additionally, the company’s Northstar Select and Northstar Response tests are designed for oncology, offering sensitive liquid biopsy solutions that guide therapy selection and provide longitudinal monitoring of cancer burden. BillionToOne’s molecular counting technologies are intended to address significant unmet needs in both the prenatal and oncology sectors, enabling earlier, safer, and more comprehensive disease detection. With a mission to improve healthcare accessibility and patient outcomes, BillionToOne plays a transformative role in the diagnostics and research segment of the healthcare market, supporting the shift toward personalized and non-invasive medicine.

CEO Dr. Oguzhan Atay Ph.D. · 713 employees · United States · https://www.billiontoone.com